Abstract: Metronomic chemotherapy is a new dosing form of chemotherapy which is in low-dosages with high frequency and continuous administration that has been rising in recent years. It can sustainably inhibit the proliferation of tumor endothelial cell, affect tumor stem cells and regulate the body's immune system. Metronomic chemotherapy may lead to disease under control in patients with advanced ovarian cancer, compared with the traditional maximum tolerated dose chemotherapy, metronomic chemotherapy is in low incidence of adverse reactions, without resistant and in good response rate, this scheme is effective for advanced ovarian cancer patients. At present, in the clinical studying with the role of metronomic chemotherapy in patients with advanced ovarian cancer, it has a positive treatment responses, which will become the new strategy for the advanced cancer patients, and improves the patient's quality of life.